miR-18a-5p promotes osteogenic differentiation of BMSC by inhibiting Notch2

Peipei He1, Zefeng Yang1, Hetong Li2

  • 1Department of Orthopedics, Shenzhen Hospital, Southern Medical University, Shenzhen, China; The Third School of Clinical Medicine, Southern Medical University, Guangzhou, China.

Bone
|August 8, 2024
PubMed

Insights

MicroRNA-18a-5p enhances bone formation in postmenopausal osteoporosis by promoting bone marrow mesenchymal stem cell differentiation. This microRNA targets Notch2, offering a new therapeutic strategy for osteoporosis treatment.

Area of Science:

  • Biomedical Science
  • Molecular Biology
  • Stem Cell Biology

Background:

  • Postmenopausal osteoporosis (PMOP) involves reduced bone density and increased fracture risk, linked to impaired bone marrow mesenchymal stem cell (BMSC) osteogenic differentiation.
  • MicroRNAs (miRNAs) regulate BMSC osteogenesis, but miR-18a-5p's role in PMOP is not fully understood, with observed reduced expression in PMOP patients.

Purpose of the Study:

  • To investigate the regulatory role of miR-18a-5p in BMSC osteogenic differentiation.
  • To elucidate the molecular mechanism by which miR-18a-5p influences osteogenesis in the context of PMOP.

Main Methods:

  • In vitro studies involving overexpression and downregulation of miR-18a-5p in BMSCs.
  • Bioinformatics analysis to identify miR-18a-5p targets, followed by dual-luciferase reporter assays and rescue experiments.
  • In vivo experiments using adenovirus-mediated miR-18a-5p overexpression in a PMOP mouse model.

Main Results:

  • Overexpression of miR-18a-5p promoted BMSC osteogenic differentiation, while its downregulation inhibited it.
  • Notch2 was identified as a direct target of miR-18a-5p, and miR-18a-5p exerted its osteogenic effects by suppressing Notch2.
  • In vivo overexpression of miR-18a-5p enhanced bone formation and alleviated PMOP symptoms in mice.

Conclusions:

  • miR-18a-5p promotes BMSC osteogenic differentiation by inhibiting Notch2.
  • miR-18a-5p represents a potential therapeutic target for treating postmenopausal osteoporosis.